Aug 13, 2020
Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA
Jun 22, 2020
CEO Renée Aguiar-Lucander Exercises Warrants and Invests SEK 15.7m (Appr. USD 1.7m) in Calliditas
Jun 12, 2020
Citigroup Notifies That Stabilization Measures Have Been Undertaken in Calliditas Therapeutics' ADSs Traded on The Nasdaq Global Select Market
Jun 05, 2020
Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States
Jun 01, 2020
Calliditas Therapeutics Launches US IPO Roadshow and Targets a Capital Raise of MUSD 75
May 14, 2020
Calliditas Publicly Files Registration Statement With SEC for a Proposed Initial Public Offering in the United States
Apr 27, 2020
Calliditas Provides a Corporate Business Update in the Context of the COVID-19 Pandemic
Mar 30, 2020
Calliditas Moves its Annual General Meeting 2020 to June 25
Jan 22, 2020
Positive Opinion Received From EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the Treatment of IgAN
Dec 19, 2019
Completion of Recruitment of Part A of the Neflgard Pivotal Phase 3 Clinical Trial by Year End
Dec 17, 2019
China IND Approval Triggers $5 Million Milestone Payment From Everest Medicines
Sep 03, 2019
Positive Feedback From FDA Significantly Benefits Ongoing NefIgArd Pivotal Phase 3 Study
Aug 15, 2019
Calliditas Therapeutics: Interim Report Q2, 2019
Aug 12, 2019
Strategic in-licensing Related to Autoimmune Hepatitis in the US Market
Jun 04, 2019
Calliditas Therapeutics to Present at Redeye Growth Day
Apr 03, 2019
Calliditas Therapeutics to Present at the Needham Healthcare Conference
Mar 04, 2019
Calliditas Therapeutics to Present at March Investor Conferences
Jan 14, 2019
Calliditas Therapeutics Appoints Frank Bringstrup as VP Regulatory Affairs
Jan 08, 2019
Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America
Nov 13, 2018
First patient Enrolled in Pivotal Clinical Phase 3 Study NEFIGARD with Lead Candidate Nefecon